Heron Therapeutics Yönetim
Yönetim kriter kontrolleri 2/4
Heron Therapeutics CEO'su Craig Collard, Apr2023 tarihinde atandı, in görev süresi 1.58 yıldır. şirketin hisselerinin 0.18% doğrudan sahiptir ve bu hisselerin değeri $ 298.72K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.4 yıl ve 3.2 yıldır.
Anahtar bilgiler
Craig Collard
İcra Kurulu Başkanı
US$5.5k
Toplam tazminat
| CEO maaş yüzdesi | n/a |
| CEO görev süresi | 1.6yrs |
| CEO sahipliği | 0.2% |
| Yönetim ortalama görev süresi | 1.4yrs |
| Yönetim Kurulu ortalama görev süresi | 3.2yrs |
Son yönetim güncellemeleri
Recent updates
Why Investors Shouldn't Be Surprised By Heron Therapeutics, Inc.'s (NASDAQ:HRTX) 30% Share Price Plunge
Nov 13
Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 30%
Nov 13Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 32%
Aug 08Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Share Price Boosted 31% But Its Business Prospects Need A Lift Too
May 30Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain
Apr 16Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its Full-Year Results
Mar 15Heron Therapeutics, Inc. (NASDAQ:HRTX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Feb 15Heron Therapeutics, Inc. (NASDAQ:HRTX) Held Back By Insufficient Growth Even After Shares Climb 27%
Dec 22Heron wins FDA nod for post-operative agent to address nausea and vomiting
Sep 16Is Heron Therapeutics (NASDAQ:HRTX) A Risky Investment?
Aug 10Heron Therapeutics Q2 2022 Earnings Preview
Aug 08Heron Therapeutics proposes 34% cut in workforce as part of cost reduction plan
Jun 30Heron Therapeutics: Cash Is A Problem Again
Mar 31Heron Therapeutics: Changing Strategy After Disappointing Earnings
Mar 03Health Check: How Prudently Does Heron Therapeutics (NASDAQ:HRTX) Use Debt?
Jan 19Heron Therapeutics: Looking For Signs Of The Bottom
Oct 07Is Heron Therapeutics (NASDAQ:HRTX) Using Too Much Debt?
Oct 03CEO
Craig Collard (58 yo)
1.6yrs
Görev süresi
US$5,486
Tazminat
Mr. Craig Alexander Collard serves as Chief Executive Officer at Heron Therapeutics, Inc. since April 3, 2023 and its Director since February 2023. He had been Chief Executive Officer of Veloxis Pharmaceut...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 1.6yrs | US$5.49k | 0.18% $ 298.7k | |
| Executive VP & CFO | 1.4yrs | US$1.76m | 0.071% $ 121.0k | |
| Executive VP & Chief Development Officer | 1.4yrs | US$1.71m | 0.068% $ 115.5k | |
| Vice President of Marketing | 1.3yrs | Veri yok | Veri yok | |
| Senior Vice President of Human Resources | 9.2yrs | Veri yok | Veri yok | |
| Senior Vice President of Oncology Care Franchise & Commercial Operations | 1.8yrs | Veri yok | Veri yok | |
| Chief Business Officer | less than a year | Veri yok | Veri yok | |
| Executive Director | no data | Veri yok | Veri yok |
1.4yrs
Ortalama Görev Süresi
55yo
Ortalama Yaş
Deneyimli Yönetim: HRTX 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.4 yıl), bu da yeni bir ekibin varlığını gösteriyor.
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 1.8yrs | US$5.49k | 0.18% $ 298.7k | |
| Independent Director | 10.8yrs | US$11.02m | 0.034% $ 58.1k | |
| Independent Director | 8.4yrs | US$70.51k | 0.034% $ 58.5k | |
| Director | no data | Veri yok | Veri yok | |
| Independent Director | 3.2yrs | US$65.63k | 0.035% $ 59.3k | |
| Independent Chairman | 1.8yrs | US$545.53k | 0.0062% $ 10.6k | |
| Independent Director | 3.2yrs | US$55.00k | 0.035% $ 59.3k |
3.2yrs
Ortalama Görev Süresi
57yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: HRTX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.2 yıldır).